A Houston doctor carries the gene that gives her an 80% chance of colon cancer. She's testing one of three vaccines designed to stop it before it starts

Dr. Stacy Norton, a 59-year-old Houston hospitalist, carries a mutation in one of the genes her body uses to proofread DNA. That single inherited typo, in a family of mismatch-repair genes, gives her up to an 80% lifetime risk of colorectal cancer and a long list of other tumors her cells are likelier to make. The condition is called Lynch syndrome, and roughly 1 million Americans share it.

Norton has already survived one Lynch-caused cancer. A different Lynch-driven brain tumor killed her sister at 25. She has two children in their 20s who inherited the same mutation. This summer, she became one of the first people in the world to test a vaccine designed not to treat cancer but to teach her immune system to intercept the next tumor before it forms.

The trial is being run at MD Anderson Cancer Center by Dr. Eduardo Vilar-Sanchez, who has spent his career studying Lynch families. The vaccine comes from the Swiss biotech Nouscom. Norton and 44 other Lynch carriers have now received it in the trial's first two phases, and the MD Anderson team reported initial results in Nature Medicine. The trial has now moved into a randomized, placebo-controlled phase.

Mismatch-repair genes act as spellcheckers for DNA mistakes during cell multiplication, and Lynch carriers' spellcheckers miss a class of errors that produce distinctive protein fragments on the surface of pre-cancerous cells. The vaccine trains the immune system to recognize those fragments and kill those cells before they form a tumor.

"Interception is the word we use," Vilar-Sanchez told CNN. "We're not curing cancer. We're trying to stop it from starting."

The Houston trial is one of at least three vaccine programs now in human testing for Lynch syndrome. Scientists are also waiting for results from a larger randomized study of ImmunityBio's Tri-Ad5 vaccine, a California company's shot that flags a different set of cancer markers. And UK regulators have authorized Moderna and the University of Oxford to begin a Phase 1/2 study of mRNA-4194, the same mRNA platform behind Moderna's COVID-19 shot, repurposed for Lynch carriers.

None of these vaccines would replace surveillance. Lynch carriers are urged to get yearly colonoscopies, far more often than the general population, because precancerous polyps can be spotted and removed before they become dangerous. The vaccines are an additional line of defense, not a substitute. Norton does not promise her children they will ever be able to skip the colonoscopy. A carrier's lifetime colorectal risk can reach as high as 80%, depending on which faulty gene they inherit; for the average person it sits around 5%.

"We know the risk," Norton said. "We do the screening. This is the hope that one day the screening could be less."

The MD Anderson team expects a larger U.S. efficacy study of the Nouscom vaccine to begin early next year. That study, not the current early-phase trial, is the one that will eventually tell researchers whether the immune system can be trained to prevent Lynch-driven cancers in people who carry the mutation. Houston Public Media and the National Cancer Institute's prevention division have both been tracking the trial; the latter hosts the public registry entry for the Nouscom study.

The early readouts are encouraging on safety and immune response. They are not an answer to the central question. For now, Lynch carriers like Norton and her two children remain in a familiar posture: get the colonoscopy, watch for the polyps, wait for the data. The vaccine adds an immune system to the watch list. The proof is still a year or more away.